Ovarian cancer: Early relapse

Patricia Pautier; Elsa Kalbacher; Thibault de la Motte Rouge; Franck Bonnetain; Anne Lesoin

doi:10.1016/S0007-4551(17)30160-1

Ovarian cancer: Early relapse

Patricia Pautier, Elsa Kalbacher, Thibault de la Motte Rouge, Franck Bonnetain, Anne Lesoin

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

Ovarian cancer: Early relapse Early relapse (primary or secondary) is defined by relapse of disease less than 6 months before the last infusion of chemotherapy (with a platinum compound). There is no carcinological surgical indication. Disease should be treated with a non-platinum single agent (pegylated liposomal doxorubicin, weekly paclitaxel, gemcitabine or topotecan). Bevacizumab can be added if patients have not already received it (level of proof 1, grade A).

Translated title of the contribution	Cancer de l'ovaire: la rechute précoce
Original language	English
Pages (from-to)	S32-S38
Journal	Bulletin du Cancer
Volume	104
DOIs	https://doi.org/10.1016/S0007-4551(17)30160-1
Publication status	Published - 1 May 2017

Access to Document

10.1016/S0007-4551(17)30160-1

Cite this

@article{220c93b2afb6401fa9070fedcef070ab,

title = "Ovarian cancer: Early relapse",

abstract = "Ovarian cancer: Early relapse Early relapse (primary or secondary) is defined by relapse of disease less than 6 months before the last infusion of chemotherapy (with a platinum compound). There is no carcinological surgical indication. Disease should be treated with a non-platinum single agent (pegylated liposomal doxorubicin, weekly paclitaxel, gemcitabine or topotecan). Bevacizumab can be added if patients have not already received it (level of proof 1, grade A).",

author = "Patricia Pautier and Elsa Kalbacher and {de la Motte Rouge}, Thibault and Franck Bonnetain and Anne Lesoin",

note = "Publisher Copyright: {\textcopyright} 2017 Elsevier Masson SAS",

year = "2017",

month = may,

day = "1",

doi = "10.1016/S0007-4551(17)30160-1",

language = "English",

volume = "104",

pages = "S32--S38",

journal = "Bulletin du Cancer",

issn = "0007-4551",

}

TY - JOUR

T1 - Ovarian cancer

T2 - Early relapse

AU - Pautier, Patricia

AU - Kalbacher, Elsa

AU - de la Motte Rouge, Thibault

AU - Bonnetain, Franck

AU - Lesoin, Anne

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Ovarian cancer: Early relapse Early relapse (primary or secondary) is defined by relapse of disease less than 6 months before the last infusion of chemotherapy (with a platinum compound). There is no carcinological surgical indication. Disease should be treated with a non-platinum single agent (pegylated liposomal doxorubicin, weekly paclitaxel, gemcitabine or topotecan). Bevacizumab can be added if patients have not already received it (level of proof 1, grade A).

AB - Ovarian cancer: Early relapse Early relapse (primary or secondary) is defined by relapse of disease less than 6 months before the last infusion of chemotherapy (with a platinum compound). There is no carcinological surgical indication. Disease should be treated with a non-platinum single agent (pegylated liposomal doxorubicin, weekly paclitaxel, gemcitabine or topotecan). Bevacizumab can be added if patients have not already received it (level of proof 1, grade A).

UR - http://www.scopus.com/inward/record.url?scp=85020815589&partnerID=8YFLogxK

U2 - 10.1016/S0007-4551(17)30160-1

DO - 10.1016/S0007-4551(17)30160-1

M3 - Article

C2 - 28625313

AN - SCOPUS:85020815589

SN - 0007-4551

VL - 104

SP - S32-S38

JO - Bulletin du Cancer

JF - Bulletin du Cancer

ER -

Ovarian cancer: Early relapse

Abstract

Access to Document

Other files and links

Cite this